Abstract
D-penicillamine (D-PA) was first recognized as a potential benefit for neonatal hyperbilirubinemia (NHBI) caused by hemolytic diseases of the newborn infant or immaturity of UDP-glucuronyltransferase enzyme. During a long-term follow up study there was a remarkedly low incidence of retrolental fibroplasia (RLF) in the infants treated with D-PA in their neonatal period.
Highlights
D-PENICILLAMINE (D-PA) was first isolated as an amine from the degradation products of penicillin by Abraham, et al in 1942 [1]
During a long-term follow up study there was a remarkedly low incidence of retrolental fibroplasia (RLF) in the infants treated with D-PA in their neonatal period
All infants < 1500 g birthweight were treated with D-PA to prevent retinopathy of prematurity (ROP)
Summary
D-PENICILLAMINE (D-PA) was first isolated as an amine from the degradation products of penicillin by Abraham, et al in 1942 [1]. During a long-term follow up study there was a remarkedly low incidence of retrolental fibroplasia (RLF) in the infants treated with D-PA in their neonatal period.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
